Search - tctmd.com

Displaying 101 - 120 of 304

Sort: Relevancy | Date

Presentation TCT 2016

Percutaneous Coronary Intervention with the ANgiolite Drug-Eluting Stent: an Optical CoHerence TOmogRaphy Study. The ANCHOR Study

Presenter: Fernando Alfonso, Ran Kornowski, Josep Rodés-Cabau

November 01, 2016

Presentation TCT 2016

Tricuspid Repair with the Trialign System

Presenter: Eric Horlick, Josep Rodés-Cabau, Charles J. Davidson

October 31, 2016

Presentation TCT 2016

Transcatheter Valve Repair Solution - When, After the Mitral Valve, the Tricuspid Should Be Treated

Presenter: Eric Horlick, Josep Rodés-Cabau, Maurizio Taramasso

October 31, 2016

Presentation TCT 2016

Trialign for Functional TR: Early US Experience

Presenter: Eric Horlick, Josep Rodés-Cabau, Charles J. Davidson

October 31, 2016

Presentation TCT 2016

Editorial Perspective: Embolic Protection in TAVR Intervention

Presenter: Josep Rodés-Cabau

October 31, 2016

Presentation TCT 2016

Severe AS With a Small Aortic Annulus

Presenter: Howard C. Herrmann, Vinod H. Thourani, Josep Rodés-Cabau

October 31, 2016

Presentation TCT 2016

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? Yes Minimize Bleeding Risk and Improve Long-term Outcomes!

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Brian K. Whisenant

October 30, 2016

Presentation TCT 2016

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First!

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Debate #1: Should Low bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? Yes As Long As Full Consent Is Provided, Let the Patient Decide!

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, David Hildick-Smith

October 30, 2016

Presentation TCT 2016

Debate #1: Should Low Bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? No Chronic Anticoagulation Should be Offered First

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Stefan C. Bertog

October 30, 2016

Presentation TCT 2016

Early Clinical Results With the Cardia LAA Occluder (and Future Studies)

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Josep Rodés-Cabau

October 30, 2016

Presentation TCT 2016

Foldax: Preclinical Results With a Novel Thin-leaflet Synthetic Valve

Presenter: Mark Reisman, Josep Rodés-Cabau, Steven J. Yakubov

October 30, 2016

Presentation TCT 2016

A Novel Bioprosthesis Designed for Optimization of Valve-in-Valve Procedures

Presenter: Mark Reisman, Josep Rodés-Cabau, Danny Dvir

October 30, 2016

Presentation TCT 2016

Total Embolic Protection in TAVR Procedures (Emboline)

Presenter: Mark Reisman, Josep Rodés-Cabau, Scott Russell

October 30, 2016

Presentation TCT 2016

The Role of Non-invasive Central Aortic Pressures In Cardiovascular Disease

Presenter: Mark Reisman, Josep Rodés-Cabau, Eyal Ben -Assa

October 30, 2016

Presentation TCT 2016

First-In-Human Experience With a Novel Active Fixation Temporary Pacing Lead: Safety and Efficacy of the Tempo Lead

Presenter: Mark Reisman, Josep Rodés-Cabau, Mark W.I. Webster

October 30, 2016

Presentation TCT 2016

Anatomical Device Imaging Reconstruction for Procedural Planning in SHD Interventions (FEOPS)

Presenter: Mark Reisman, Josep Rodés-Cabau, Matthieu De Beule

October 30, 2016

News Daily News

La Endocarditis Infecciosa Post-TAVR se asocia a Diabetes, Regurgitación Aórtica Residual en un Extenso Registro

Yael L. Maxwell

September 14, 2016

News Daily News

Infective Endocarditis After TAVR Linked to Diabetes, Residual Aortic Regurgitation in Large Registry

Yael L. Maxwell

September 14, 2016

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

Advertisement

Percutaneous Coronary Intervention with the ANgiolite Drug-Eluting Stent: an Optical CoHerence TOmogRaphy Study. The ANCHOR Study

Tricuspid Repair with the Trialign System

Transcatheter Valve Repair Solution - When, After the Mitral Valve, the Tricuspid Should Be Treated

Trialign for Functional TR: Early US Experience

Editorial Perspective: Embolic Protection in TAVR Intervention

Severe AS With a Small Aortic Annulus

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? Yes Minimize Bleeding Risk and Improve Long-term Outcomes!

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First!

Debate #1: Should Low bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? Yes As Long As Full Consent Is Provided, Let the Patient Decide!

Debate #1: Should Low Bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? No Chronic Anticoagulation Should be Offered First

Early Clinical Results With the Cardia LAA Occluder (and Future Studies)

Foldax: Preclinical Results With a Novel Thin-leaflet Synthetic Valve

A Novel Bioprosthesis Designed for Optimization of Valve-in-Valve Procedures

Total Embolic Protection in TAVR Procedures (Emboline)

The Role of Non-invasive Central Aortic Pressures In Cardiovascular Disease

First-In-Human Experience With a Novel Active Fixation Temporary Pacing Lead: Safety and Efficacy of the Tempo Lead

Anatomical Device Imaging Reconstruction for Procedural Planning in SHD Interventions (FEOPS)

La Endocarditis Infecciosa Post-TAVR se asocia a Diabetes, Regurgitación Aórtica Residual en un Extenso Registro

Infective Endocarditis After TAVR Linked to Diabetes, Residual Aortic Regurgitation in Large Registry

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content